Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Allograft rejection mediated by memory T cells is resistant to regulation.
Yang J, Brook MO, Carvalho-Gaspar M, Zhang J, Ramon HE, Sayegh MH, Wood KJ, Turka LA, Jones ND. Yang J, et al. Among authors: brook mo. Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19954-9. doi: 10.1073/pnas.0704397104. Epub 2007 Nov 27. Proc Natl Acad Sci U S A. 2007. PMID: 18042727 Free PMC article.
Feasibility, long-term safety, and immune monitoring of regulatory T cell therapy in living donor kidney transplant recipients.
Harden PN, Game DS, Sawitzki B, Van der Net JB, Hester J, Bushell A, Issa F, Brook MO, Alzhrani A, Schlickeiser S, Scotta C, Petchey W, Streitz M, Blancho G, Tang Q, Markmann J, Lechler RI, Roberts ISD, Friend PJ, Hilton R, Geissler EK, Wood KJ, Lombardi G. Harden PN, et al. Among authors: brook mo. Am J Transplant. 2021 Apr;21(4):1603-1611. doi: 10.1111/ajt.16395. Epub 2021 Feb 2. Am J Transplant. 2021. PMID: 33171020 Free PMC article. Clinical Trial.
Transplantation Without Overimmunosuppression (TWO) study protocol: a phase 2b randomised controlled single-centre trial of regulatory T cell therapy to facilitate immunosuppression reduction in living donor kidney transplant recipients.
Brook MO, Hester J, Petchey W, Rombach I, Dutton S, Bottomley MJ, Black J, Abdul-Wahab S, Bushell A, Lombardi G, Wood K, Friend P, Harden P, Issa F. Brook MO, et al. BMJ Open. 2022 Apr 15;12(4):e061864. doi: 10.1136/bmjopen-2022-061864. BMJ Open. 2022. PMID: 35428650 Free PMC article.
Late Treatment With Autologous Expanded Regulatory T-cell Therapy After Alemtuzumab Induction Is Safe and Facilitates Immunosuppression Minimization in Living Donor Renal Transplantation.
Brook MO, Hennessy C, Hester J, Hammad S, Alzhrani A, Rombach I, Dutton S, Lombardi G, Wood KJ, Friend P, Harden PN, Issa F. Brook MO, et al. Transplantation. 2024 Nov 1;108(11):2278-2286. doi: 10.1097/TP.0000000000005065. Epub 2024 Oct 22. Transplantation. 2024. PMID: 38845088 Free PMC article. Clinical Trial.
Regulatory T cell therapy is associated with distinct immune regulatory lymphocytic infiltrates in kidney transplants.
McCallion O, Cross AR, Brook MO, Hennessy C, Ferreira R, Trzupek D, Mulley WR, Kumar S, Soares M, Roberts IS, Friend PJ, Lombardi G, Wood KJ, Harden PN, Hester J, Issa F. McCallion O, et al. Among authors: brook mo. Med. 2024 Dec 27:100561. doi: 10.1016/j.medj.2024.11.014. Online ahead of print. Med. 2024. PMID: 39731908 Free article.
17 results